# Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)

> **NCT03980041** · PHASE2 · COMPLETED · sponsor: **Infinity Pharmaceuticals, Inc.** · enrollment: 49 (actual)

## Conditions studied

- Bladder Cancer
- Urothelial Carcinoma
- Solid Tumor
- Advanced Cancer

## Interventions

- **DRUG:** IPI-549 (eganelisib)
- **DRUG:** Nivolumab
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03980041
- **Lead sponsor:** Infinity Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-25
- **Primary completion:** 2020-11-30
- **Final completion:** 2022-11-15
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2022-11-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03980041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03980041, "Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03980041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*